Adma Biologics Inc (NASDAQ: ADMA)’s stock price has soared by 3.01 in relation to previous closing price of 5.98. Nevertheless, the company has seen a gain of 0.82% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-15 that It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), ADMA Biologics (ADMA), Lantheus (LNTH) and Skyward (SKWD) are well-poised to gain.
Is It Worth Investing in Adma Biologics Inc (NASDAQ: ADMA) Right Now?
Moreover, the 36-month beta value for ADMA is 0.45. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADMA is 219.51M and currently, short sellers hold a 3.32% of that float. On April 17, 2024, ADMA’s average trading volume was 2.55M shares.
ADMA’s Market Performance
The stock of Adma Biologics Inc (ADMA) has seen a 0.82% increase in the past week, with a 2.84% rise in the past month, and a 24.95% gain in the past quarter. The volatility ratio for the week is 4.14%, and the volatility levels for the past 30 days are at 3.65% for ADMA. The simple moving average for the last 20 days is -2.03% for ADMA’s stock, with a simple moving average of 39.22% for the last 200 days.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at 5.30% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.88% of loss for the given period.
Volatility was left at 3.65%, however, over the last 30 days, the volatility rate increased by 4.14%, as shares surge +3.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.78% upper at present.
During the last 5 trading sessions, ADMA rose by +0.82%, which changed the moving average for the period of 200-days by +69.70% in comparison to the 20-day moving average, which settled at $6.30. In addition, Adma Biologics Inc saw 36.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from ELMS STEVE, who sale 411,829 shares at the price of $6.08 back on Mar 19 ’24. After this action, ELMS STEVE now owns 2,115,671 shares of Adma Biologics Inc, valued at $2,503,920 using the latest closing price.
ELMS STEVE, the Director of Adma Biologics Inc, sale 49,887 shares at $6.01 during a trade that took place back on Mar 18 ’24, which means that ELMS STEVE is holding 2,527,500 shares at $299,821 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.34 for the gross margin
The net margin for Adma Biologics Inc stands at -0.13. The total capital return value is set at 0.08. Equity return is now at value -19.67, with -8.33 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 0.97. The interest coverage ratio of the stock is 0.86.
Currently, EBITDA for the company is 29.96 million with net debt to EBITDA at 3.11. When we switch over and look at the enterprise to sales, we see a ratio of 5.79. The receivables turnover for the company is 9.42for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.16.
Conclusion
To wrap up, the performance of Adma Biologics Inc (ADMA) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
